Skip to main content
Edwards Lifesciences Logo
Edwards Lifesciences Logo

RESILIA tissue surgical valve portfolio

Discover the RESILIA tissue portfolio difference

PROVEN IMG
PROVEN IMG
PROVEN IMG

Proven PERIMOUNT Platform

RESILIA Tissue Durabilityimg
RESILIA Tissue Durabilityimg
RESILIA Tissue Durabilityimg

RESILIA Tissue Durability

Future Focused img
Future Focused img
Future Focused img

Future  Focused

Innovation built on a proven platform

RESILIA tissue valves are built on the Carpentier-Edwards PERIMOUNT valve platform, whose performance is backed by 30 years of durability data, including the largest long-term study of a bioprosthetic valve.

Innovation built on a proven platform IMG
Innovation built on a proven platform IMG
Innovation built on a proven platform IMG
Innovation built on a proven platform IMG
Innovation built on a proven platform IMG
Innovation built on a proven platform IMG

Innovation that transformed the tissue valve landscape

RESILIA tissue technology

RESILIA tissue* builds on the trusted ThermaFix process and is treated with a novel preservation technology to resist calcification more effectively and allow for dry storage.1

img
img
img

+ Calcium-blocking technology

Stable-capping permanently blocks free aldehydes to prevent calcium binding within the tissue

img
img
img

+ Glycerolization

Mitigates calcium-attracting glutaraldehyde residuals and enables dry tissue storage for increased ease of use

72% less calcium content after 8 months

RESILIA tissue showed significant improvement in calcium-blocking properties1


(follow-up exceeded the 5-month duration required by regulatory agencies)

img
img
img

*No clinical data are available that evaluate the long-term impact of RESILIA tissue in patients.
†RESILIA tissue tested against tissue from commercially available bovine pericardial valves from Edwards in a juvenile sheep model. Flameng, et al. J Thorac Cardiovasc Surg. 2015;149:340-345. 


a. 6900P is an older valve model being discontinued and is not available for commercial use.

img
img
img

Taking performance and durability to new heights

The RESILIA tissue surgical valve portfolio is backed by a robust, growing base of clinical evidence attesting to its hemodynamic performance and durability. RESILIA tissue has been applied to INSPIRIS and MITRIS valves.

IMG
IMG
IMG
IMG
IMG
IMG

Clinically stable hemodynamics2,3

img
img
img
img
img
img

Durability data2,3

img
img
img
img
img
img

RESILIA tissue valves showed less SVD-related HVD vs conventional valves in a comparison of COMMENCE and PARTNER IIA trials4

See the clinical evidence

Innovation that keeps future procedures in mind

Expanding patient possibilities with VFit technology

1 / 4
Expanding patient possibilities with VFit technology
Expanding patient possibilities with VFit technology
Expanding patient possibilities with VFit technology
Largest opening area, with the lowest gradients
Largest opening area, with the lowest gradients
Largest opening area, with the lowest gradients
Designed to prevent obstruction
Designed to prevent obstruction
Designed to prevent obstruction
Delivering the best visibility for future interventions
Delivering the best visibility for future interventions
Delivering the best visibility for future interventions
Expanding patient possibilities with VFit technology
Expanding patient possibilities with VFit technology
Expanding patient possibilities with VFit technology

Expanding patient possibilities with VFit technology

Largest opening area, with the lowest gradients
Largest opening area, with the lowest gradients
Largest opening area, with the lowest gradients

Largest opening area, with the lowest gradients

Designed to prevent obstruction
Designed to prevent obstruction
Designed to prevent obstruction

Designed to prevent obstruction

Delivering the best visibility for future interventions
Delivering the best visibility for future interventions
Delivering the best visibility for future interventions

Delivering the best visibility for future interventions

Expanding patient possibilities with VFit technology

Largest opening area, with the lowest gradients

Designed to prevent obstruction

Delivering the best visibility for future interventions

Featured Products

Explore our current RESILIA tissue products

inspiris resilia
inspiris resilia
inspiris resilia

INSPIRIS RESILIA aortic valve

mitris resilia thumb
mitris resilia thumb
mitris resilia thumb

MITRIS RESILIA mitral valve

Resources

At the cutting edge of innovation
At the cutting edge of innovation
At the cutting edge of innovation

RESILIA tissue portfolio

Download brochure
inspiris thumbnail
inspiris thumbnail
inspiris thumbnail

INSPIRIS RESILIA aortic valve

Download fact sheet
MITRIS fact sheet
MITRIS fact sheet
MITRIS fact sheet

MITRIS RESILIA mitral valve

Download fact sheet

The Edwards Advantage

We are committed to providing your institution, clinicians and staff with the highest levels of customer service and support to ensure seamless product implementation and ongoing use, including:

Monday through Friday, 8:00am to 17:00pm CET

(+44).163.527.7334 tech_support_UK@edwards.com
Magna ease
Magna ease
Magna ease

Contact a sales representative

If you would like further information about our privacy policy, please click here.

Would you like to opt-in to receive future email communications from Edwards Lifesciences?

This includes notification of future symposia, forums, conference activities, product updates, and educational events.

References

  1. Flameng W, Hermans H, Verbeken E, et al. A randomized assessment of an advanced tissue preservation technology in the juvenile sheep model. J Thorac Cardiovasc Surg. 2015;149(1):340-345. 
  2. Beaver T, Bavaria J, Griffith B, et al. Seven-year outcomes following aortic valve replacement with a novel tissue bioprosthesis. J Thorac Cardiovasc Surg. 2023;x:1-11. 
  3. Heimansohn DA, Baker C, Rodriguez E, et al. Mid-term outcomes of the COMMENCE trial investigating mitral valve replacement using a bioprosthesis with a novel tissue. JTCVS Open. 2023;15:151-163. 
  4. Bartus K, Bavaria J, Thourani V, et al. Structural hemodynamic valve deterioration durability of RESILIA-tissue versus contemporary aortic bioprostheses. J Comp Eff Res. 2023;12(3):e220180. 
  5. Saxon JT, Allen K, Cohen D, et al. Bioprosthetic valve fracture during valve-in-valve TAVR: bench to bedside. Interv Cardiol. 2018;13(1):20-26. 
  6. Saxon JT, Allen K, Cohen D, et al. Complications of bioprosthetic valve fracture as an adjunct to valve-in-valve TAVR. Structural Heart. 2019;3(2):92-99. 
  7. Wang DD, O’Neill B, Caranasos T, et al. Comparative differences of mitral valve-in-valve implantation: A new mitral bioprosthesis versus current mosaic and epic valves. Catheter Cardiovasc Interv. 2022;99(3):934-942.

No clinical data are available that evaluate the long-term impact of RESILIA tissue in patients. Additional clinical data for up to 10 years of follow-up are being collected to monitor the long-term safety and performance of RESILIA tissue.

Refer to device instructions for important warnings related to VFit technology. These features have not been observed in clinical studies to establish the safety and effectiveness of the model 11500A for use in valve-in-valve procedures. VFit technology is available on sizes 19–25 mm.

Medical device for professional use

Medical device for professional use

For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).